C3a (70-77)
Cat.No:CLP0236 Solarbio
CAS:63555-63-5
Molecular Formula:C35H61N13O10
Molecular Weight:823.95
Purity:≥95%
Appearance:Lyophilized powder
Storage:Store at -20℃,2 years.(Avoid freeze/thaw cycles)
Qty:
Size:
{{cart_num}}
My CartCAS:63555-63-5
Molecular Formula:C35H61N13O10
Molecular Weight:823.95
Purity:≥95%
Appearance:Lyophilized powder
Storage:Store at -20℃,2 years.(Avoid freeze/thaw cycles)
Qty:
Size:
Product Type | Peptides |
CAS | 63555-63-5 |
Sequence(1LC) | ASHLGLAR |
Sequence(3LC) | Ala-Ser-His-Leu-Gly-Leu-Ala-Arg |
Molecular Formula | C35H61N13O10 |
Molecular Weight | 823.95 |
Purity | ≥95% |
Appearance | Lyophilized powder |
Solubility | H2O:100 mg/mL; *Ultrasonic solubilization; |
Salt Form | Trifluoroacetate salt |
Source | Synthetic |
Storage | Store at -20℃,2 years.(Avoid freeze/thaw cycles) |
Category/Label | Tag Peptides |
Background | This octapeptide is a COOH-terminal fragment of the C3a anaphylatoxin peptide. On a molar basis, this peptide possesses 1-2% of the biological activities of C3a. It causes contraction of rodent ileum and uterus, release of vasoactive amines from rat mast cells, and increases vascular permeability in guinea pig and human skin. Both purified C3a and synthetic C3a (70-77), which retains partially the activity of anaphylatoxin, are shown to interact directly with human lymphocytes. |
Reference | [1] Tony E. Hugli and Bruce W. Erickson. PNAS 74, 1826 (1977); [2]Payan, D. et al. J. exp Med 156, 756 (1982). |
Unit | Bottle |
Specification | 1mg 5mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.